Revealing the temporal evolution of cerebrospinal fluid (CSF) biomarkers during aging is critical to understanding disease pathogenesis and developing early diagnoses and interventions for Alzheimer's disease (AD). CSF was obtained from 549 cognitively normal subjects between 18 and 93 years of age. 12 AD-related biomarkers were evaluated, including amyloid β (Aβ42, Aβ40, Aβ42/Aβ40 ratio), hyperphosphorylated tau (P-tau), neuronal injury/degeneration (T-tau, NFL, NSE, H-FABP, VILIP-1), neuroinflammation biomarkers (YKL-40, TREM2), and α-synuclein (α-synuclein). Associations between these biomarkers and age as well as apolipoprotein E (APOE) ε4 status were evaluated, and the associations among biomarkers were assessed. CSF Aβ42, P-tau, and T-tau levels exhibited nonlinear associations with age, among which Aβ42 was significantly modulated by APOE ε4 status. Specifically, an accelerated decline in Aβ42 levels occurred at 45.69 years of age in the APOE ε4+ group, which was almost 23 years earlier than that in the APOE ε4- group (68.02 years). The age-related change pattern of CSF P-tau is similar to that of T-tau, with both increasing slightly with age but showing an accelerated change at ≈60 years of age in the APOE ε4+ group. All the other biomarkers except for α-synuclein were linearly associated with age, and APOE ε4 status had no effect on these associations. Most biomarkers were positively correlated with each other except for Aβ42/Aβ40 ratio. The evolution of AD-related biomarkers in CSF varies throughout the adult lifespan, with the APOE ε4 allele modifying the temporal changes in CSF Aβ42 levels, as well as potentially influencing P-tau and T-tau levels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/acel.70036 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!